These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32183592)

  • 1. Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective.
    Pearson H; Marshall LV; Carceller F
    Pediatr Hematol Oncol; 2020 Aug; 37(5):412-423. PubMed ID: 32183592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
    Schmid I; Häberle B; Albert MH; Corbacioglu S; Fröhlich B; Graf N; Kammer B; Kontny U; Leuschner I; Scheel-Walter HG; Scheurlen W; Werner S; Wiesel T; von Schweinitz D
    Pediatr Blood Cancer; 2012 Apr; 58(4):539-44. PubMed ID: 21922643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion.
    Kaibori M; Matsushima H; Ishizaki M; Kosaka H; Matsui K; Nakatani M; Kariya S; Yamaguchi T; Yoshida K; Yoshii K; Sekimoto M
    Cancer Invest; 2022 Jan; 40(1):81-89. PubMed ID: 34236269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
    Berk V; Kaplan MA; Tonyali O; Buyukberber S; Balakan O; Ozkan M; Demirci U; Ozturk T; Bilici A; Tastekin D; Ozdemir N; Unal OU; Oflazoglu U; Turkmen E; Erdogan B; Uyeturk U; Oksuzoglu B; Cinkir HY; Yasar N; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(12):7367-9. PubMed ID: 24460304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
    Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
    Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
    Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State of the art and perspectives in pediatric hepatocellular carcinoma.
    Digiacomo G; Serra RP; Turrini E; Tiri A; Cavazzoni A; Alfieri R; Bertolini P
    Biochem Pharmacol; 2023 Jan; 207():115373. PubMed ID: 36513143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
    Tanaka T; Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
    Oncology; 2020; 98(9):621-629. PubMed ID: 32434180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial.
    Mokdad AA; Zhu H; Beg MS; Arriaga Y; Dowell JE; Singal AG; Yopp AC
    Target Oncol; 2019 Oct; 14(5):541-550. PubMed ID: 31429027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of pediatric hepatocellular carcinoma: A multimodal approach.
    Kohorst MA; Warad DM; Matsumoto JM; Heimbach JK; El-Youssef M; Arndt CAS; Rodriguez V; Nageswara Rao AA
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28631359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
    Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
    J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
    Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
    Ishizaki M; Kaibori M; Matsui K; Ikeda H; Yoshida K; Okazaki K; Kariya S; Tanigawa N; Nakatake R; Matsushima H; Sakaguchi T; Kon M
    Cancer Invest; 2017 Apr; 35(4):271-276. PubMed ID: 28272913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
    Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
    Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.